New molecular staging with G-factor supplements TNM classification in gastric cancer: a multicenter collaborative research by the Japan Society for Gastroenterological Carcinogenesis G-Project committee

Gastric Cancer

Volumn 18, Issue 1, 2015, Pages 119-128

  Sawada, Tetsuji ^a   Yashiro, Masakazu ^a   Sentani, Kazuhiro ^b   Oue, Naohide ^b   Yasui, Wataru ^b   Miyazaki, Kohji ^c   Kai, Keita ^c   Fushida, Sachio ^d   Fujimura, Takashi ^d   Ohira, Masaichi ^a   Kakeji, Yoshihiro ^e   Natsugoe, Shoji ^f   Shirabe, Ken ^g   Nomura, Sachiyo ^h   Shimada, Yutaka ⁱ   Tomita, Naohiro ^j   Hirakawa, Kosei ^a   Maehara, Yoshihiko ^g  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c SAGA UNIVERSITY   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

^e KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f KAGOSHIMA UNIVERSITY   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ UNIVERSITY OF TOYAMA   (Japan)

^j HYOGO COLLEGE OF MEDICINE   (Japan)

more..

Author keywords

G factor; Gastric cancer; Molecular staging; TNM classification

Indexed keywords

CLAUDIN 18; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR; MATRILYSIN; OLFACTOMEDIN 4; PROTEIN P53; REGENERATING ISLET DERIVED FAMILY MEMBER 4; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; CLAUDIN; CLDN18 PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; MMP7 PROTEIN, HUMAN; TUMOR MARKER; VEGFA PROTEIN, HUMAN;

ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION; PROTEIN EXPRESSION; RECURRENCE RISK; STOMACH CANCER; CLASSIFICATION; CLINICAL TRIAL; HEALTH CARE ORGANIZATION; KAPLAN MEIER METHOD; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROGNOSIS; STOMACH NEOPLASMS;

BIOMARKERS, TUMOR; CLAUDINS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 7; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; SOCIETIES, SCIENTIFIC; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84916229852     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-014-0338-2     Document Type: Article

References (25)

1. Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol. 2003;21:19–22.
2. Japanese Gastric Cancer A. Japanese classification of gastric carcinoma—2nd English edition. Gastric Cancer. 1998;1:10–24.
3. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.
4. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol. 1997;15:826–32.
5. Maeda K, Kang SM, Onoda N, Ogawa M, Sawada T, Nakata B, et al. Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology. 1998;55:594–9.
6. Maehara Y, Tomoda M, Hasuda S, Kabashima A, Tokunaga E, Kakeji Y, et al. Prognostic value of p53 protein expression for patients with gastric cancer—a multivariate analysis. Br J Cancer. 1999;79:1255–61.
7. Kakeji Y, Koga T, Sumiyoshi Y, Shibahara K, Oda S, Maehara Y, et al. Clinical significance of vascular endothelial growth factor expression in gastric cancer. J Exp Clin Cancer Res. 2002;21:125–9.
8. Fondevila C, Metges JP, Fuster J, Grau JJ, Palacin A, Castells A, et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer. 2004;90:206–15.
9. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res. 2004;10:3069–75.
10. White JD, Hewett PW, Kosuge D, McCulloch T, Enholm BC, Carmichael J, et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res. 2002;62:1669–75.
11. Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 2006;94:1823–32.
12. Ajisaka H, Yonemura Y, Miwa K. Correlation of lymph node metastases and expression of matrix metalloproteinase-7 in patients with gastric cancer. Hepatogastroenterology. 2004;51:900–5.
13. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Investig. 2001;19:554–68.
14. Oue N, Kuniyasu H, Noguchi T, Sentani K, Ito M, Tanaka S, et al. Serum concentration of Reg IV in patients with colorectal cancer: overexpression and high serum levels of Reg IV are associated with liver metastasis. Oncology. 2007;72:371–80.
15. Oue N, Mitani Y, Aung PP, Sakakura C, Takeshima Y, Kaneko M, et al. Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J Pathol. 2005;207:185–98.
16. Oue N, Sentani K, Noguchi T, Ohara S, Sakamoto N, Hayashi T, et al. Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer. 2009;125:2383–92.
17. Sanada Y, Oue N, Mitani Y, Yoshida K, Nakayama H, Yasui W. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol. 2006;208:633–42.
18. Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA. Molecular staging individualizing cancer management. J Surg Oncol. 2012;105:468–74.
19. Zhang YJ, Fang JY. Molecular staging of gastric cancer. J Gastroenterol Hepatol. 2008;23:856–60.
20. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005;23:3526–35.
21. Siemer S, Lehmann J, Loch A, Becker F, Stein U, Schneider G, et al. Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol. 2005;173:33–7.
22. Goldstraw P. New staging system: how does it affect our practice? J Clin Oncol. 2013;31:984–91.
23. Yoon HM, Ryu KW, Nam BH, Cho SJ, Park SR, Lee JY, et al. Is the new seventh AJCC/UICC staging system appropriate for patients with gastric cancer? J Am Coll Surg. 2012;214:88–96.
24. Kologlu M, Kama NA, Reis E, Doganay M, Atli M, Dolapci M. A prognostic score for gastric cancer. Am J Surg. 2000;179:521–6.
25. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.